LITTLE FALLS, N.J., Jan. 8, 2014 /PRNewswire/ -- CANTEL MEDICAL CORP. (NYSE: CMN), through its Crosstex subsidiary, has further expanded its sterility assurance monitoring business with the acquisition of Sterilator Company, Inc. Based in Cuba, NY, Sterilator Company is a high-quality manufacturer of biological indicators and supplies for sterility assurance products, which are used to accurately monitor the effectiveness of sterilization processes. Sterilator serves both the medical and industrial markets, and has been a long-time supplier of self-contained biological indicators, dual species spore strips and culture media to our dental and hospital healthcare disposable business.
Gary Steinberg, President and CEO of Crosstex said, "This acquisition allows us to add one of our key long-standing suppliers of biological indicators to our portfolio, providing a strategic benefit to our overall sterility assurance monitoring business. I am also pleased that we will retain Sterilator's current leadership, who will serve an integral role in new product development and R&D initiatives in sterility assurance."
Andrew Krakauer, President and CEO of Cantel Medical added, "This acquisition further enhances our capabilities as a leading provider of sterility assurance monitoring products to the medical industry. Furthermore, this addition strengthens our product development capabilities, enabling Cantel to continue providing the best infection prevention and control products and solutions to our customers."
About Cantel Medical Corp.
Cantel Medical is a leading global company dedicated to delivering innovative infection prevention and control products and services for patients, caregivers, and other healthcare providers which improve outcomes, enhance safety and help save lives. Our products include specialized medical device reprocessing systems for endoscopy and renal dialysis, advanced water purification equipment, sterilants, disinfectants and cleaners, sterility assurance monitoring products for hospitals and dental clinics, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates, hollow fiber membrane filtration and separation products, and specialty packaging for infectious and biological specimens. Additionally, we provide technical service for our products. For further information, visit the Cantel website at www.cantelmedical.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.
SOURCE Cantel Medical Corp.